Patient research priority setting partnership in human T-cell lymphotropic virus type I.
HTLV-1
collaboration
communication
priority setting
research needs
user involvement
Journal
Health expectations : an international journal of public participation in health care and health policy
ISSN: 1369-7625
Titre abrégé: Health Expect
Pays: England
ID NLM: 9815926
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
revised:
27
07
2023
received:
08
11
2022
accepted:
02
08
2023
medline:
10
11
2023
pubmed:
14
8
2023
entrez:
14
8
2023
Statut:
ppublish
Résumé
Human T-cell lymphotropic virus type 1 (HTLV-1) is a chronic infection affecting 5-10 million people worldwide. Ten percent develop HTLV-1-associated diseases, and 3%-5% develop HTLV-1-associated myelopathy (HAM)/tropical spastic paraparesis. Low health-related quality of life (HRQoL) is a significant concern for those with HTLV-1, and little is known about how it impacts daily life or what patients need from healthcare services. To address this, we report on patient involvement workshops aimed at identifying research priorities for HTLV-1 health service provision. Participants recruited through HTLV-1 clinics in England attended six 90-min virtual workshops over 10 months, and two 60-min consolidation workshops. Content developed iteratively from topic focussed group discussions. All workshops were video-recorded with consent, transcribed verbatim and thematically analysed. Using consensus voting rounds, participants individually ranked their top six and then collectively their top three research priorities from the themes inferred from the analysis. A final feedback session explored the experiences of participating in the workshops. Twenty-seven people with HTLV-1 engaged with the workshops with up to 22 participants attending each meeting. The majority were diagnosed with HAM (n = 22). The top three research priorities were identified as understanding disease progression, psychosocial wellbeing, and information and knowledge. Participants valued being asked to set research priorities that directly addressed their needs and enjoyed the workshops. They stressed the importance of patient advocates for promoting research that positively impacts everyday life. This is the first of this type of research engagement with people with HTLV-1 in the United Kingdom. Participants identified several avenues of investigation that could lead to improvements in healthcare services and HRQoL. Participants believed the workshops signified the start of a conversation to progress person-centred and meaningful research in HTLV-1. People living with HTLV-1 were involved in the iterative design, conduct, analysis, writing and dissemination of this project through the patient involvement workshops. As a result of this engagement, a patient led advisory group has been set up to assist with the dissemination of the findings.
Identifiants
pubmed: 37578191
doi: 10.1111/hex.13848
pmc: PMC10632630
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2418-2427Informations de copyright
© 2023 The Authors. Health Expectations published by John Wiley & Sons Ltd.
Références
Clin Infect Dis. 2015 Jul 1;61(1):49-56
pubmed: 25820277
J Acquir Immune Defic Syndr. 2000 May 1;24(1):86-7
pubmed: 10877505
BMJ. 2000 Mar 4;320(7235):611-2
pubmed: 10698878
J Neurovirol. 2019 Feb;25(1):1-8
pubmed: 30291566
Rev Soc Bras Med Trop. 2021 Jan 29;54:e06232020
pubmed: 33533820
Rev Neurol (Paris). 2012 Mar;168(3):257-69
pubmed: 22405461
J Neurovirol. 2022 Dec;28(4-6):473-482
pubmed: 35908019
PLoS Negl Trop Dis. 2019 May 1;13(5):e0006967
pubmed: 31042700
J Neurovirol. 1998 Dec;4(6):586-93
pubmed: 10065900
Res Involv Engagem. 2016 Apr 27;2:15
pubmed: 29062516
Adv Ther. 2018 Feb;35(2):135-152
pubmed: 29411267
Neurol Clin Pract. 2021 Feb;11(1):49-56
pubmed: 33968472
Lancet Oncol. 2014 Oct;15(11):e517-26
pubmed: 25281470
J Acquir Immune Defic Syndr (1988). 1990;3(11):1096-101
pubmed: 2213510
J Relig Health. 2022 Feb;61(1):540-551
pubmed: 33417057
Pilot Feasibility Stud. 2015 Oct 23;1:35
pubmed: 27965813
J Neurovirol. 2021 Dec;27(6):838-848
pubmed: 33405200
Euro Surveill. 2017 May 18;22(20):
pubmed: 28598325
Braz J Infect Dis. 2016 Nov - Dec;20(6):592-598
pubmed: 27768899
PLoS Negl Trop Dis. 2020 Oct 16;14(10):e0008761
pubmed: 33064742
J Multidiscip Healthc. 2015 Feb 23;8:117-25
pubmed: 25759588
Neurology. 2003 Dec 9;61(11):1588-94
pubmed: 14663047
PLoS Negl Trop Dis. 2012;6(6):e1705
pubmed: 22720112
Health Expect. 2023 Dec;26(6):2418-2427
pubmed: 37578191
Lancet Infect Dis. 2007 Apr;7(4):266-81
pubmed: 17376384
PLoS Negl Trop Dis. 2009 Nov 24;3(11):e487
pubmed: 19936247
Pharmacol Ther. 2021 Feb;218:107669
pubmed: 32835825
J Patient Rep Outcomes. 2020 May 4;4(1):31
pubmed: 32367401
AIDS Res Hum Retroviruses. 2013 Feb;29(2):359-64
pubmed: 22894552
J Neurol Neurosurg Psychiatry. 2010 Dec;81(12):1336-40
pubmed: 20660921